ArriVent BioPharma, Inc.
ArriVent BioPharma (Nasdaq: AVBP) is a clinical-stage biopharmaceutical company developing cancer medicines, with an initial focus on solid tumors. Its lead candidate, firmonertinib, is an EGFR-mutant-selective tyrosine kinase inhibitor being studied in non-small cell lung cancer, including first-line treatment of… From the company’s description.
In fiscal 2025, ArriVent BioPharma, Inc. reported a net loss of $166.31M. Operations used $160.59M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What ArriVent BioPharma, Inc. does
In the company’s own words
ArriVent BioPharma (Nasdaq: AVBP) is a clinical-stage biopharmaceutical company developing cancer medicines, with an initial focus on solid tumors. Its lead candidate, firmonertinib, is an EGFR-mutant-selective tyrosine kinase inhibitor being studied in non-small cell lung cancer, including first-line treatment of tumors with EGFR exon 20 insertion and PACC mutations. The company is also developing ARR-217, a CDH17-targeting antibody-drug conjugate for gastrointestinal cancers, which is in Phase 1, and advancing ARR-002, a preclinical ADC candidate. ArriVent’s pipeline also includes ADC programs pursued through research and development collaborations. The company licenses and collaborates on oncology assets for development and commercialization outside greater China, which comprises mainland China, Hong Kong, Macau and Taiwan; firmonertinib is approved and marketed by its partner in China for certain NSCLC patients. Founded in 2021, ArriVent licensed worldwide ex-China rights to firmonertinib that year and has since expanded its pipeline through collaborations and additional licensing agreements. Its website is https://www.arrivent.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NEWTOWN SQUARE, PA
- Fiscal year end
- December
- CIK
- 1868279
- SIC
- 2834
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns ArriVent BioPharma, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · ArriVent BioPharma, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do ArriVent BioPharma, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of ArriVent BioPharma, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in ArriVent BioPharma, Inc.'s last four quarterly filings that the numbers alone won't show?”